Homocysteine induces energy imbalance in rat skeletal muscle: Is creatine a protector?

Cell Biochemistry and Function

Volumn 31, Issue 7, 2013, Pages 575-584

  Kolling, Janaína ^a   Scherer, Emilene B S ^a   Siebert, Cassiana ^a   Hansen, Fernanda ^a   Torres, Felipe V ^a   Scaini, Giselli ^b   Ferreira, Gabriela ^b   de Andrade, Rodrigo B ^a   Gonçalves, Carlos A S ^a   Streck, Emílio L ^b   Wannmacher, Clovis M D ^a   Wyse, Angela T S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Creatine; Energy metabolism; Gastrocnemius skeletal muscle; Severe hyperhomocysteinemia

Indexed keywords

CITRATE SYNTHASE; CREATINE; CREATINE KINASE; HOMOCYSTEINE; ISOCITRATE DEHYDROGENASE; MALATE DEHYDROGENASE; PYRUVATE KINASE; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROCNEMIUS MUSCLE; GLUCOSE OXIDATION; HOMEOSTASIS; HYPERHOMOCYSTEINEMIA; MALE; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

CREATINE; ENERGY METABOLISM; GASTROCNEMIUS SKELETAL MUSCLE; SEVERE HYPERHOMOCYSTEINEMIA;

ANIMALS; CELL SURVIVAL; CITRIC ACID CYCLE; CREATINE; DRUG SYNERGISM; ENERGY METABOLISM; FEMALE; GLUCOSE; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MALE; MITOCHONDRIA; MUSCLE, SKELETAL; OXIDATION-REDUCTION; RATS; RATS, WISTAR;

EID: 84884975507     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2938     Document Type: Article

References (89)

1. Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors 2010; 36: 19-24.
2. Perry DJ. Hyperhomocysteinemia. Baillieres Clin Haematol 1999; 12: 451-477.
3. Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004; 35: 345-347.
4. McCully KS. Chemical pathology of homocysteine. V. Thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases. Ann Clin Lab Sci 2011; 41: 301-314.
5. Troen AM, Shea-Budgell M, Shukitt-Hale B, Smith DE, Selhub J, Rosenberg IH. B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. Proc Natl Acad Sci USA 2008; 105: 12474-12479.
6. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds). McGraw-Hill: New York, 2001; 1279-1327.
7. Minagawa H, Watanabe A, Akatsu H, et al. Homocysteine, another risk factor for Alzheimer disease, impairs apolipoprotein E3 function. J Biol Chem 2010; 285: 38382-38388.
8. Işiklar OO, Barutcuoǧlu B, Kabaroǧlu C, et al. Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases? Clin Biochem 2012; 45: 1325-1330.
9. Wang X, Cui L, Joseph J, et al. Homocysteine induces cardiomyocyte dysfunction and apoptosis through p38 MAPK-mediated increase in oxidant stress. J Mol Cell Cardiol 2012; 52: 753-760.
10. Tomasini DN, Segu B. Systemic considerations in bilateral central retinal vein occlusion. Optometry 2007; 78: 402-408.
11. Khanna S, Kapoor P, Pillai KK, Vohora D. Homocysteine in neurological disease: a marker or a cause? CNS Neurol Disord Drug Targets 2011; 10: 361-369.
12. Huang CR, Chang WN, Tsai NW, Lu CH. Serial nerve conduction studies in vitamin B12 deficiency-associated polyneuropathy. Neurol Sci 2011; 32: 183-186.
13. Leishear K, Ferrucci L, Lauretani F, et al. Vitamin B12 and homocysteine levels and 6-year change in peripheral nerve function and neurological signs. J Gerontol A Biol Sci Med Sci 2012; 67: 537-543.
14. Kley RA, Vorgerd M, Tarnopolsky MA. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2007; 24: CD004760.
15. Pathi B, Kinsey ST, Howdeshell ME, Priester C, McNeill RS, Locke BR. The formation and functional consequences of heterogeneous mitochondrial distributions in skeletal muscle. J Exp Biol 2012; 215: 1871-1883.
16. Chinta SJ, Andersen JK. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 2006; 41: 1442-1448.
17. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60: 748-766.
18. Ferreira AGK, Lima DD, Delwing D, et al. Proline impairs energy metabolism in cerebral cortex of young rats. Metab Brain Dis 2010; 25: 161-168.
19. Delwing D, Tagliari B, Streck EL, Wannamacher CM, Wajner M, Wyse AT. Reduction of energy metabolism in rat hippocampus by arginine administration. Brain Res 2003; 983: 58-63.
20. +-ATPase, acetylcholinesterase and catalase activities in striatum, hippocampus and cerebral cortex of rats. Int J Dev Neurosci 2006; 24: 411-417.
21. Delwing D, Delwing D, Chiarani F, Kurek AG, Wyse AT. Proline reduces brain cytochrome c oxidase: prevention by antioxidants. Int J Dev Neurosci 2007; 25: 17-22.
22. +-ATPase activity inhibition and memory impairments caused by chronic hyperhomocysteinemia during rat development. Int J Dev Neurosci 2007; 25: 545-552.
23. Barja G. Free radicals and aging. Trends Neurosci 2004; 27: 595-600.
24. Linford NJ, Schriner SE, Rabinovitch PS. Oxidative damage and aging: spotlight on mitochondria. Cancer Res 2006; 66: 2497-2499.
25. Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 2007; 292: 670-686.
26. Tarnopolsky MA. Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell Biochem 2007; 46: 183-204.
27. Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2011; 2: CD004760.
28. Owen L, Sunram-Lea SI. Metabolic Agents that Enhance ATP can Improve Cognitive Functioning: A Review of the Evidence for Glucose, Oxygen, Pyruvate, Creatine, and L-Carnitine. Nutrients 2011; 3: 735-755.
29. Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Bharath MM, Shankar SK. Mitochondrial function in human brains is affected by pre and postmortem factors. Neuropathol Appl Neurobiol 2012; DOI:10.1111/j.1365-2990.2012.01285.x.
30. Da Silva D, Ausina P, Alencar EM, Coelho WS, Zancan P, Sola-Penna M. Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice. IUBMB Life 2012; 64(9): 766-774.
31. Mattevi A, Bolognesi M, Valentini G. The allosteric regulation of pyruvate kinase. FEBS Lett 1996; 389: 15-19.
32. Lee JC, Herman P. Structural and functional energetic linkages in allosteric regulation of muscle pyruvate kinase. Methods Enzymol 2011; 488: 185-217.
33. Pierron D, Wildman DE, Hüttemann M, Markondapatnaikuni GC, Aras S, Grossman LI. Cytochrome c oxidase: Evolution of control via nuclear subunit addition. Biochim Biophys Acta 2012; 1817: 590-597.
34. Schnyder T, Gross H, Winkler H, Eppenberger HM, Wallimann T. Structure of the mitochondrial creatine kinase octamer: high-resolution shadowing and image averaging of single molecules and formation of linear filaments under specific staining conditions. J Cell Biol 1991; 112: 95-101.
35. Wallimann T, Wyss M, Brdiczka D, Nicolay K. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 28: 121-140.
36. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
37. Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci 2012; 37: 309-316.
38. Walker JB, Hannan JK. Creatine biosynthesis during embryonic development. False feedback suppression of liver amidinotransferase by n-acetimidoylsarcosine and 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine). Biochemistry 1976; 15: 2519-2522.
39. Xu LB, Wang ZX, Qi D, et al. A preliminary study on the effects of the exogenous creatine phosphate on rat masseter muscle after unilateral chew. Hua Xi Kou Qiang Yi XueZaZhi 2010; 28: 348-351.
40. Deminice R, Vilhena R, Portari GV, Jordão AA. Suplementação de creatina, homocisteína e estresse oxidativo. Medicina 2007; 40: 368-377.
41. Terjung RL, Clarkson P, Eichner ER, et al. American college of sports medicine roundtable, The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 2000; 32: 706-717.
42. Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience 2002; 112: 243-260.
43. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006; 67: 1262-1264.
44. Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: 6-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 57: 694-702.
45. Beal FM. Neuroprotective effects of creatine. Amino Acids 2011; 40: 1305-1313.
46. Streck EL, Delwing D, Tagliari B, et al. Brain energy metabolism is compromised by the metabolites accumulating in homocystinuria. Neurochem Int 2003; 43: 597-602.
47. Streck EL, Matté C, Vieira PS, et al. Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia. Biochim Biophys Acta 2003; 1637: 187-192.
48. Pearson AM, Young RB. Diseases and disorders of muscle. Adv Food Nutr Res 1993; 37: 339-423.
49. Majors AK, Sengupta S, Jacobsen DW, Pyeritz RE. Upregulation of smooth muscle cell collagen production by homocysteine-insight into the pathogenesis of homocystinuria. Mol Genet Metab 2002; 76: 92-99.
50. Streck EL, Matte C, Vieira PS, et al. Reduction of Na(+), K(+)-ATPase activity in hippocampus of rats subjected to chemically induced hyperhomocysteinemia. Neurochem Res 2002; 27: 1593-1598.
51. Kolling J, Wyse AT. Creatine prevents the inhibition of energy metabolism and lipid peroxidation in rats subjected to GAA administration. Metab Brain Dis 2010; 2: 331-338.
52. Persky AM, Brazeau GA, Hochhaus G. Pharmacokinetics of the dietary supplement creatine. Clin Pharmacokinet 2003; 42: 557-574.
53. Snow RJ, Murphy RM. Factors influencing creatine loading into human skeletal muscle. Exerc Sport Sci Rev 2003; 31: 154-158.
54. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-210.
55. Maizels EZ, Ruderman NB, Goodman MN, Lau D. Effect of acetoacetate on glucose metabolism in the soleus and extensor digitorum longus muscles of the rat. Biochem J 1977; 162: 557-568.
56. Kaushik VK, Young ME, Dean DJ, Kurowski TG, Saha AK, Ruderman NB. Regulation of fatty acid oxidation and glucose metabolism in rat soleus muscle: effects of AICAR. Am J Physiol Endocrinol Metab 2001; 281: 335-340.
57. Leong SF, Lai JCK, Lim L, Clark JB. Energy-metabolizing enzymes in brain regions of adult and aging rats. J Neurochem 1981; 37: 1548-1556.
58. Srere PA. Citrate synthase. Methods Enzymol 1969; 13: 3-11.
59. Plaut GWE. Isocitrate dehydrogenases from bovine heart. Methods Enzymol 1969; 13: 34-42.
60. Kitto GB. Intra- and extramitochondrial malate dehydrogenases from chicken and tuna heart. Methods Enzymol 1969; 13: 106-116.
61. Fischer JC, Ruitenbeek W, Berden JA, et al. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta 1985; 153: 23-36.
62. Rustin P, Chretien D, Bourgeron T, Gérard B, Rötig A, Saudubray JM, Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228: 35-51.
63. Hughes BP. A method for the estimation of serum creatine kinase and it use in comparing creatine kinase and aldolase activity in normal and pathological sera. Clin Chim Acta 1962; 7: 597-603.
64. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-267.
65. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Ver 2000; 80: 1107-1213.
66. Taes YE, Delanghe JR, De Bacquer D, et al. Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. Kidney Int 2004; 66: 2422-2428.
67. Stead LM, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism. Adv Enzyme Regul 2004; 44: 321-333.
68. Taes YE, Delanghe JR, De Vriese AS, Rombaut R, Vam Camp RJ, Lameire NH. Creatine supplementation decrease homocysteine in an animal model of uremia. Kidney Int 2003; 64: 1331-1337.
69. Mccarty MF. Supplemental creatine may decrease serum homocysteine and abolish the homocysteine 'gender gap' by suppressing endogenous creatine synthesis. Med Hypotheses 2001; 56: 5-7.
70. Bodamer OA, Sahoo T, Beaudet AL, et al. Creatine metabolism in combined methylmalonic aciduria and homocystinuria. Ann Neurol 2005; 57: 557-560.
71. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab 2001; 281: 1095-1100.
72. Gualano B, Ferreira DC, Sapienza MT, Seguro AC, Lancha AHJ. Effect of short-term high-dose creatine supplementation on measured GFR in a young man with a single kidney. Am J Kidney Dis 2010; 55: 7-9.
73. Nicastro H, Gualano B, De Moraes WM, et al. Effects of creatine supplementation on muscle wasting and glucose homeostasis in rats treated with dexamethasone. Amino Acids 2012; 42: 1695-1701.
74. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52: 854-857.
75. Kley RA, Tarnopolsky MA, Vorgerd M. Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 2008; 79: 366-367.
76. Gualano B, Painelli VS, Roschel H, et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol 2011; 111: 749-756.
77. + channel independent mechanism. Diabetologia 1996; 39(suppl.): A31.
78. Op't Eijnde B, Jijakli H, Hespel P, Malaisse WJ. Creatine supplementation increases soleus muscle creatine content and lowers the insulinogenic index in an animal model of inherited type 2 diabetes. Int J Mol Med 2006; 17: 1077-1084.
79. Sora I, Richman J, Santoro G, et al. The cloning and expression of a human creatine transporter. Biochem Biophys Res Commun 1994; 204: 419-427.
80. Steenge GR, Lambourne J, Casey A, Macdonald IA, Greenhaff PL. Stimulatory effect of insulin on creatine accumulation in human skeletal muscle. Am J Physiol 1998; 275: 974-979.
81. Wallimann T, Schlattner U. Creatine kinases: a cornerstone for structural research in the phosphagen kinase family. FASEB J 2010; 24: 7.
82. Huang RF, Hsu YC, Lin HL, Yang FL. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 2001; 131: 33-38.
83. Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T. Inhibition of the mitochondrial permeability transition by creatine kinase substrates, Requirement for microcompartmentation. J Biol Chem 2003; 278: 17760-17766.
84. Messer JI, Jackman MR, Willis WT. Pyruvate and citric acid cycle carbon requirements in isolated skeletal muscle mitochondria. Am J Physiol Cell Physiol 2004; 286: 565-572.
85. Gronow GH, Cohen JJ. Substrate support for renal functions during hypoxia in the perfused rat kidney. Am J Physiol 1984; 247: 618-631.
86. Pisarenko OI. Mechanisms of myocardial protection by amino acids: facts and hypotheses. Clin Exp Pharmacol Physiol 1996; 23: 627-633.
87. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000; 97: 2826-2831.
88. Scholte HR, Luyt-Houwen IE, Vaandrager-Verduin MH. The role of the carnitine system in myocardial fatty acid oxidation: carnitine deficiency, failing mitochondria and cardiomyopathy. Basic Res Cardiol 1987; 82: 63-73.
89. Jacobs RA, Boushel R, Wright-Paradis C, et al. Mitochondrial function in human skeletal muscle following high altitude exposure. Exp Physiol 2012 [Epub ahead of print].